



FOUNDATION FUNDING OPPORTUNITIES: MARCH 5, 2021

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

**Have you updated your MGH Researcher profile?
Go to <https://researchers.mgh.harvard.edu/> today!**

1. Clinical Scientist Development Awards, American Laryngological, Rhinological, and Otolological Society, Inc. (Triological Society)

The Triological Society and the American College of Surgeons combined competitive grant program provides supplemental funding to otolaryngologists-head and neck surgeons who have received a new NIH Mentored Clinical Scientist Development Award (K08/K23) or have an existing award with a minimum of 3 years remaining in the funding period as of October 1 of the application year.

This award is a means to facilitate the research career development of otolaryngologists-head and neck surgeons, with the expectation that the awardee will have sufficient pilot data to submit a competitive R01 proposal prior to the conclusion of the K award.

Eligibility requirements (partial list):

- Applicants must be MD otolaryngologist-head and neck surgeons and members of the American College of Surgeons.

Citizenship: United States

Award Amount: \$400,000 paid over 5 years

Indirect Costs: None

Application Deadline: June 1, 2021

Website: <https://www.triological.org/research-grants/#trioacs>



Do you want to learn more about identifying external funding opportunities? Please [click here](#) to request a research consultation with **Amy Robb** or see ECOR's website for information on the [Pivot database](#).

2. ASH Bridge Grant Program, American Society of Hematology (ASH)

Since 2013, the ASH Bridge Grant Program has been one of the Society's most critical programs and has demonstrated the Society's commitment to protecting the careers of those who are dedicated to hematology research. Each year awards are granted to ASH members who applied for an NIH R01 grant or equivalent and were scored but not funded. ASH Bridge Grants are intended to help sustain recipients' research and contribute to their retention in hematology investigation while they reapply.

Proposals that fall within any of the categories discussed below are encouraged.

- Basic Research
- Translational Research
- Patient-Oriented Clinical Research
- Outcomes-Based Research

Eligibility requirements (partial list):

- The ASH Bridge Grant is open to ASH members at various career stages who meet the eligibility requirements.
- MDs, PhDs, and MD-PhDs conducting malignant or non-malignant hematology research are encouraged to apply.
- The applicant must have submitted to the NIH in the past 18 months a hematology-related R01 or R01-equivalent application that was scored but not funded.

Citizenship: Unrestricted

Award Amount: \$150,000

Indirect Costs: None

Application Deadline: May 1, 2021

Website: <https://www.hematology.org/awards/career-enhancement-and-training/bridge-grant>

3. Scholar Awards, American Society of Hematology (ASH)

Since 1985, the ASH Scholar Award has helped ease the transition between training and the establishment of an independent career in hematology research by providing partial salary or other support during that critical period. The award offers three funding opportunities for hematology researchers.

- Fellow Scholar Award: Applicants must be in mentored, postdoctoral training positions with five or fewer years of research experience following completion of their terminal degree.
- Fellow to Faculty Scholar Award: Applicants must be in mentored, postdoctoral training positions, possess five to eight years of research experience following completion of their terminal degree, and have available no more than \$150,000 annually in research funding.

- Junior Faculty Scholar Award: Applicants must have between eight and 13 years of research experience following completion of their terminal degree. Applicants who hold independent faculty level positions must apply for the Junior Faculty Award.

Eligibility requirements (partial list):

- Be an ASH member in good standing at the time of the letter of intent deadline and plan to maintain membership for the duration of the award term.
- If you have successfully competed for a substantial award (e.g. NIH R01 or equivalent grant) as the PI or co-PI before the application (not LOI) deadline, you are no longer eligible for the Scholar Award.

Citizenship: United States or Canada

Award Amount:

- Fellow Scholar Award: \$100,000 paid over 2- years
- Fellow to Faculty Scholar Award: \$125,000 paid over 2-3 years
- Junior Faculty Scholar Award: \$150,000 paid over 2-3 years

Indirect Costs: None

LOI Deadline: May 3, 2021

(Invited) Application Deadline: August 2, 2021

Website: <https://www.hematology.org/awards/career-enhancement-and-training/scholar-award>

4. Special Call for Research to Address Gastrointestinal Complications, Angelman Syndrome Foundation, Inc. (ASF) **NEW!**

There is a special call for research focused on gastrointestinal complications in Angelman syndrome.

The ASF Scientific Advisory Committee identified the following areas of unmet need in AS research. Priority will be given to the following topics:

- Projects studying or correcting the heterozygous effect of non-UBE3A genes in deletion.
- Projects studying the potential results of increasing UBE3A after therapies or for some subtypes of AS.
- Projects studying delivery of therapies and potential for improvement.
- Symptomatic therapies that impact the daily life of people with Angelman syndrome and their families.

Proposals that do not address these topics are still welcome and will be given full consideration.

Citizenship: Unrestricted

Award Amount: \$100,000

Indirect Costs: 10%

Application Deadline: March 15, 2021

Website: <https://www.angelman.org/as-research/call-for-proposals/>

5. Grants, Caplan Foundation for Early Childhood

The Caplan Foundation for Early Childhood is an incubator of promising research and development projects that appear likely to improve the welfare of young children, from infancy through 7 years, in the United States. Welfare is broadly defined to include physical and mental health, safety, nutrition, education, play, familial support, acculturation, societal integration and childcare.

The Foundation provides funding in the following areas:

1. Early Childhood Welfare

Children can only reach their full potential when all aspects of their intellectual, emotional and physical development are optimally supported.

Providing a safe and nurturing environment is essential as is imparting the skills of social living in a culturally diverse world. Therefore, the Foundation supports projects that seek to perfect child rearing practices and to identify models that can provide creative, caring environments in which all young children thrive.

2. Early Childhood Education and Play

Research shows that children need to be stimulated as well as nurtured, early in life, if they are to succeed in school, work and life. That preparation relates to every aspect of a child's development, from birth to age seven, and everywhere a child learns - at home, in childcare settings and in preschool.

We seek to improve the quality of both early childhood teaching and learning, through the development of innovative curricula and research based pedagogical standards, as well as the design of imaginative play materials and learning environments.

3. Parenting Education

To help parents create nurturing environments for their children, we support programs that teach parents about developmental psychology, cultural child rearing differences, pedagogy, issues of health, prenatal care and diet, as well as programs which provide both cognitive and emotional support to parents.

Citizenship: United States

Award Amount: Unspecified

Indirect Costs: 15%

LOI Deadline: May 31, 2021

Website: <http://earlychildhoodfoundation.org/>

6. Career Development Awards, Crohn's and Colitis Foundation of America, Inc. (CCFA)

The objective of the Career Development Awards are mentored awards intended to facilitate the development of individuals with research potential to prepare for a career of independent basic and/or clinical investigation in the area of inflammatory bowel disease (IBD).

Proposal MUST be relevant to IBD (Crohn's disease and/or ulcerative colitis) and must contain a career development plan detailing a training plan, mentorship plan, and describe how receiving this award will facilitate the transition to independence. Only one application is allowed per applicant per submission date. Simultaneous submission of a Senior Research Award and Training Award is not permitted.

Citizenship: Unrestricted

Award Amount: \$90,000-\$270,000 paid over 1-3 years

Indirect Costs: None

LOI Deadline: May 5, 2021

Full Proposal Deadline: July 20, 2021

Website: <http://www.crohnscolitisfoundation.org/science-and-professionals/research/grants-fellowships/career-development-awards.html>

7. IBD Ventures Initiative, Crohn's and Colitis Foundation of America, Inc. (CCFA)

IBD Ventures is a funding mechanism intended to accelerate the discovery and development of novel research-based products with the potential to alleviate suffering caused by inflammatory bowel disease (IBD).

The IBDV program is not a traditional research grant mechanism. Its objective is to identify and support organizations that will benefit from partnership with the Foundation in pursuit of product discovery and development.

Citizenship: Unrestricted

Award Amount: \$500,000 for 1 year

Indirect Costs: 10%

LOI Deadline: August 6, 2021

Website: <https://www.crohnscolitisfoundation.org/research/grants-fellowships/entrepreneurial-investing>

8. Research Fellowship Awards, Crohn's and Colitis Foundation of America, Inc. (CCFA)

Research Fellowship Awards are intended to support individuals in the post-doctoral phase of their career, to develop skills related to basic and/or clinical investigation in the field of inflammatory bowel disease (IBD), or Crohn's disease and ulcerative colitis.

Proposals MUST be relevant to IBD (Crohn's Disease or ulcerative colitis) and must include a training and a mentoring plan. Awardees must devote a minimum of 80% of his/her professional time directly to the project.

Eligibility requirements (partial list):

- MD applicants in excess of seven years and PhD applicants in excess of five years of receiving their terminal degree should explain how additional support in the post-doctoral phase would benefit their development beyond their current training.
- Applicants must hold an MD and/or PhD (or equivalent degree). Candidates holding MD degrees must have two years of experience after receiving their terminal degree -- one year of which must be documented research experience relevant to IBD. Applicants holding PhDs must have at least one year of documented post-doctoral research relevant to IBD.
- Individuals who are already well established in the field of IBD research are not considered eligible for this award. Applicants should identify a senior investigator to serve as a mentor throughout the term of the award.

Citizenship: Unrestricted

Award Amount: \$58,250-\$174,750 paid over 1-3 years

Indirect Costs: None

LOI Deadline: May 5, 2021

(Invited) Full Proposal Deadline: Jul 20, 2021

Website: <http://www.ccfa.org/science-and-professionals/research/grants-fellowships/research-fellowship-awards.html>

9. Senior Research Awards, Crohn's and Colitis Foundation of America, Inc. (CCFA)

The Objective is to provide established researchers with funds to generate sufficient preliminary data to become competitive for funds from other sources such as the National Institutes of Health (NIH).

Proposal must be relevant to Inflammatory Bowel Disease (IBD) or Crohn's disease and/or ulcerative colitis. Only one application is allowed per applicant per submission date.

Simultaneous submission of a Senior Research Award and a Training Award is not permitted.

Citizenship: Unrestricted

Award Amount: \$ \$105,300-\$315,900 paid over 1-3 years

Indirect Costs: 10%

LOI Deadline: May 5, 2021

Resubmissions do not require an LOI. Resubmissions are allowed within three years of the initial application submission. After three years, a new LOI is required.

Application Deadline: July 20, 2021

Website: <http://www.ccfa.org/science-and-professionals/research/grants-fellowships/senior-research-awards.html>

10. Clinical Repurposing for Rare Pediatric Diseases, Cures Within Reach **NEW!**

The Charles H. Hood Foundation is excited to partner with Cures Within Reach (CWR) on building a portfolio of pediatric repurposing projects that could quickly lead to clinical breakthroughs for the pediatric population.

This Request for Proposals (RFP) is seeking clinical trials using repurposed treatments for any rare pediatric disease for an upcoming CureAccelerator Live! event. CureAccelerator Live! is a philanthropic pitch event, raising awareness of and funding for innovative repurposing research projects, with up to \$50,000 funding for the winning project announced that evening. This RFP seeks clinical repurposing trials, up to five of which will be selected to pitch at this live event, held virtually on June 10-11, 2021.

Repurposing research tests already approved and available therapies to determine if they are safe and effective in treating a different indication, thereby improving patient outcomes and quality of life. Repurposed therapies can be used alone or in combination with other therapies. Therapies must already be FDA, EMA or any other regulatory agency approved or otherwise readily available for human use. Repurposing research may also:

- Test combination therapies in order to increase efficacy, including combining the current disease treatment with a repurposed treatment
- Modify current treatment protocols to make them more effective, helping more patients for longer periods of time
- Repurpose therapies approved for use in adults into pediatric indications, or vice versa

Citizenship: Unrestricted

Award Amount: \$50,000

Cures Within Reach will provide no more than 80% of the REQUESTED PROJECT FUNDING, and the institution, organization or company proposing the research will match at least 20% of the REQUESTED PROJECT FUNDING.

Indirect Costs: None

Application Deadline: March 17, 2021

Website: <https://www.cureswithinreach.org/programs/funding-opportunities-rfps/>

11. Pediatric Research Grants, Gerber Foundation

The Foundation's mission focuses on infants and young children. Accordingly, priority is given to projects that improve the nutrition, care and development of infants and young children from the first year before birth to three years of age.

The Foundation is particularly interested in fresh approaches to solving common, everyday problems or emerging issues within our defined focus area. Projects should focus on issues

faced by care providers that, when implemented, will improve the health, nutrition and/or developmental outcomes for infants and young children. The board is particularly looking for practical solutions that can be easily and rapidly implemented on a broad scale with a predictable time frame to clinical application.

Major target areas for research include:

- New diagnostic tools that may be more rapid, more specific, more sensitive, less invasive
- New treatment regimens that are improved or novel, less stressful or painful, more targeted, have less side effects, provide optimal dosing
- Symptom relief
- Preventative measures
- Assessment of deficiencies or excesses (vitamins, minerals, drugs, etc.)
- Risk assessment tools or measures for environmental hazards, trauma, etc.

Note that the Foundation is looking for projects that will result in 'new' information, treatments or tools that will result in a change in practice. The board rarely funds projects that are focused on sharing current information with parents or caregivers (parent or provider educational programs).

Citizenship: United States

Award Amount: \$350,000 paid over 3 years

Indirect Costs: 10%

Concept Paper Deadline: May 15, 2021

(Invited) Full Proposal Deadline: August 15, 2021

Website: <http://www.gerberfoundation.org/how-to-apply/>

12. Novel Ideas and Approaches for Developing New Clinical Measures to Improve Diagnosis, Gordon and Betty Moore Foundation (GBMF)

The Gordon and Betty Moore Foundation's Diagnostic Excellence Initiative recently announced a funding opportunity soliciting novel ideas and approaches for developing new clinical quality measures to improve diagnosis, specifically targeting three major categories of disease: acute vascular events (such as stroke and myocardial infarction), infections (such as sepsis and pneumonia) and cancer (such as lung and colorectal). Successfully funded proposals will form our second cohort of grantees in this area.

Award Amount: \$500,000 paid over 18 months

Indirect Costs: 12.5%

Application Deadline: May 10, 2021

Website: <https://www.moore.org/initiative-strategy-detail?initiativeId=diagnostic-excellence>

13. IARS Mentored Research Awards (IMRA), International Anesthesia Research Society (IARS)

The IARS Awards are intended to support investigations that will further the understanding of clinical practice in anesthesiology and related sciences. The grants are intended to help create future leaders and prepare applicants to apply for independent research funding.

Applications for the IMRA may be in any area of investigation (clinical, translational, basic science), but must have ultimate relevance to the broad practice of anesthesiology and its subspecialties.

Eligibility requirements (partial list):

- Principal applicants for IMRA must be members of the International Anesthesia Research Society who have yet to establish substantial independent research funding or who are initiating a new area of research.

Citizenship: Unrestricted

Award Amount: \$175,000 paid over 2 years

Indirect Costs: None

Application Deadline: April 30, 2021

Website: http://iars.org/iars-mentored-research-award/?utm_source=header

14. Pichichero Family Foundation Research Development, Vaccines for Children Initiative Award in Pediatric Infectious Diseases, Pediatric Infectious Diseases Society (PIDS)

Established in 2016, the Pichichero Family Foundation Research Awards in Pediatric Infectious Diseases support outstanding investigators performing translational or clinical research focused on pediatric infectious diseases. Specifically, the awards prioritize research involving vaccine development or that expands our knowledge of pathogenesis and moves the field towards the development of new vaccines and therapeutics. One- to two-year grants are available for applicants at any level in their professional career and all members of PIDS are encouraged to apply. Applications by members of sister pediatric infectious disease societies (e.g. ESPID, SLIPE, ASPID, WSPID, AfSPID and ANZPID) will also be enthusiastically accepted and considered as long as the applicant is also a member of PIDS.

Scope of Work: The award is intended to support translational and clinical research involving vaccine development and/or pathogenesis or host-pathogen interaction moves the field towards the development of new vaccines and therapeutics. Studies of new uses of existing vaccines (e.g., use in a special population) may also be considered; however, preference will be made for studies that advance new knowledge, new insights into vaccine and immunotherapeutic development, pathogenesis and host-pathogen interactions. Research proposals that focus principally on disease surveillance or vaccine attitudes/hesitancy are unlikely to be funded.

Eligibility requirements (partial list):

- Pediatric infectious diseases physicians and scientists (MD and PhD) are encouraged to apply.
- All applicants must be members of PIDS.
- Established investigators should provide evidence for how the proposed work represents a new direction that is not currently or previously funded.

Citizenship: Unrestricted

Award Amount: \$50,000-\$100,000 paid over 1-2 years

Indirect Costs: 8%

Application Deadline: July 15, 2021

Website: <https://pidsfoundation.org/research/research-awards/pichichero-award-in-pediatric-infectious-diseases.html>

15. BRAF-mutant melanoma: treatment selection and side effect management, Pfizer Global Medical Grants (GMG) **NEW!**

Projects that will be considered for Pfizer support will focus on:

1. Increasing understanding of clinical data to inform treatment selection for patients with BRAF-mutant melanoma, and
2. Increasing understanding of treatment side effects and how they can be managed by providers involved in the care of patients with BRAF-mutant melanoma

It is not our intent to support clinical research projects via this RFP. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Citizenship: Canada or United States

Award Amount: \$100,000

Indirect Costs: 28%

Application Deadline: April 2, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

16. BRAF-mutant metastatic colorectal cancer: Management of patients, Pfizer Global Medical Grants (GMG) **NEW!**

Projects that will be considered for Pfizer support will focus on:

- Increasing the understanding of the relatively poor prognosis of BRAF-mutant mCRC compared to non-BRAF-mutant mCRC1
- Improving the integration of biomarker testing results into treatment of patients with mCRC
- Increasing the understanding of mCRC treatment outcomes and side effect management.

It is not our intent to support clinical research projects via this RFP. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Citizenship: Canada or United States

Award Amount: \$200,000

Indirect Costs: 28%

Application Deadline: April 9, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

17. Education and Support for Patients with Locally-Advanced or Metastatic Bladder Cancer, Pfizer Global Medical Grants (GMG) **NEW!**

The intent of this RFP is to support independent education initiatives for patients with locally-advanced or metastatic bladder cancer and their caregivers.

The goal is to increase understanding of 1st line maintenance treatment and overall treatment options in the 1st line setting for locally-advanced or metastatic bladder cancer.

Grants available to patient-focused organizations working in the bladder cancer area interested in developing educational materials or resources for patients including:

- Novel decision making tools to support provider-patient decision making and drive patient engagement in their care.
- Innovative communication channels, digital programs, and enduring resources.

Citizenship: United States

Award Amount: \$150,000

Indirect Costs: 28%

Application Deadline: April 7, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

18. Pre-clinical & Translational Research in Multiple Myeloma, Pfizer Global Medical Grants (GMG) **NEW!**

Only pre-clinical projects with a focus on these areas of interest will be considered for Pfizer support at this time:

- Correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRDnegativity, and response to prior therapy
- Understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS, OS)
- Mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion)
- Correlation between Soluble BCMA and BCMA expression on myeloma cells
- Impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels

- Mechanistic understanding of the impact of anti-myeloma agents (e.g., IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity
- Exploring in-vitro or in-vivo novel combinations with elranatamab (PF06863135)

IMPORTANT NOTES:

- Studies can be in-vitro or in-vivo or use existing patient samples (e.g., blood, bone marrow aspirates, etc.)
- A limited amount of the Pfizer asset elranatamab (PF-06863135) is available and can be requested through this RFP for non-clinical studies
- The clinical ISR (Investigator Sponsored Research) program for elranatamab is expected to launch at a later date.

Citizenship: Canada or United States

Award Amount: \$150,000

Indirect Costs: 28%

Application Deadline: May 17, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

19. Research Grants, The Cure JM Foundation (Cure JM)

The mission of Cure JM is to find better treatments and a cure for Juvenile Myositis, and improve the lives of families affected by JM. Approximately 2 to 4 children in a million in the United States are diagnosed with JM each year.

Perinent, but not exhaustive, list of priorities includes:

- Conducting analyses on samples and/or data available from innovative treatment clinical studies.
- Collaboration with pharma companies or other research organizations that are developing new therapies that may have utility in the treatment of juvenile myositis. The collaboration may comprise generation of clinical protocols for new treatments and a defined route to funding a clinical study. Such proposals should include solid evidence of access to the therapy being proposed for investigation.
- Clinical protocols for repurposed drugs for the treatment of juvenile myositis. Such proposals should include solid evidence of access to the therapy being proposed for investigation and a defined route to funding a clinical study.
- Investigations of in vitro or in vivo models of juvenile myositis with the objective of development of new therapies.

Citizenship: Unspecified

Award Amount: \$150,000 paid over 2 years

Indirect Costs: None

LOI Deadline: May 14, 2021

Application Deadline: June 15, 2021

Website: <http://www.curejm.org/research/funding.php?id=medpro>

20. Deborah Munroe Noonan Memorial Fund, Health Resources in Action (HRiA)/The Medical Foundation

The Deborah Munroe Noonan Memorial Research Fund, established in 1947 by Frank M. Noonan in memory of his mother, continues its proud tradition of supporting improvements in the quality of life for children with disabilities. Recognizing that children's health services and supports are provided in a wide range of community settings as well as hospitals, the Noonan Research program welcomes research proposals from both nonprofit organizations and academic institutions that serve children with physical or developmental disabilities and associated health-related complications. Eligible organizations and target populations must be within the Fund's geographic area of interest of Greater Boston. Neither a faculty position nor an advanced degree is required.

Proposals for basic science research will not be considered, nor will applications for capital costs such as buildings, renovations, or major equipment items. The Noonan Fund does not support direct service, primary prevention projects, or primary medical conditions such as obesity or device development. Drug trials are not supported by the Noonan Research Fund.

The Sara Elizabeth O'Brien Trust Award focused on Blindness will not be offered in 2021 as part of the Noonan program.

Citizenship: Unrestricted

Award Amount: \$80,000-\$160,000 paid over 1-2 years

Indirect Costs: 20%

Application Deadline: April 7, 2021

Website: <https://hria.org/tmf/noonan/>